12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

OBI-1 regulatory update

Ipsen and Inspiration said FDA granted Fast Track designation to OBI-1 to treat acquired hemophilia A. The recombinant porcine Factor VIII is in Phase III testing for the indication, with a BLA submission to FDA slated for next half. The product...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >